# Venue and submission preparation for manuscript v0.8

Assessment and official-page access date: **3 November 2026, America/Chicago** (4 November UTC). This memo assesses the completed v0.7 evidence being revised into v0.8. It updates the [earlier venue memo](JOURNAL_FIT_2026-11-03.md), whose main evidence was v0.4 and whose public-example and reproduction work was then incomplete. It does not submit the paper, contact editors, acquire clinical data or release another experiment.

**Recommendation: prepare a PLOS Digital Health Research Article reporting a method. Keep Journal of Biomedical Informatics as a conditional methodological alternative. Treat npj Digital Medicine as a stretch option with a present fit gap, not the default submission.** The ranking below is our assessment of the manuscript and official policies; it is not an editorial decision or acceptance forecast.

## What the paper can now offer

The central use is an analyzable virtual cohort when individual construction data are inaccessible or absent. The scientific Agent selects a joint law, interprets study-qualified estimates as numerical constraints, and supplies explicit assumptions for information the publications do not identify. Existing observations can support other system modes, but complete-cohort generation is the principal empirical application.

The manuscript now contains three completed settings:

- External-evidence development in CHNS and ENSANUT: 20 Agent and four statistical constructions, 72 final tables, with lower discrepancies for five of six focal effects and a worse CHNS BMI result.
- A separate CHNS study with accessible target summaries: useful reconstruction by six Agent constructions, with no additional-stage revision improvement.
- An HRS public-model example: one Agent and one reconstructed published-law model, six valid longitudinal tables, complete effect reporting and retained weak-effect/upper-tail mismatches.

The completed [aggregate reproduction entry point](../docs/REPRODUCING_MANUSCRIPT_v07.md) and [independent review](../reproducibility/INDEPENDENT_REVIEW_v07_2026-11-03.md) improve inspectability: Tables 2-4 and the quantitative figures can be rebuilt from public aggregates. They do not add biomedical validation or provide a clinical rerun.

The contribution should therefore lead with **scientific model construction from heterogeneous published evidence and demonstrated analytical uses**, rather than the fact that an Agent writes code, the number of synthetic rows, or audit counts. Its comparison with predecessors is a capability-and-information comparison, supplemented by the completed empirical comparisons. The user has not chosen a universal-superiority claim, and none is needed to state this contribution.

## Three-venue comparison

| Venue and article type | Verified official facts | Assessment of the current manuscript |
|---|---|---|
| **PLOS Digital Health — Research Article reporting a method** | Methods and tools are eligible; its Database Creation and Curation section explicitly covers synthetic-data generation and validation. A method paper uses the Research Article category. The criteria include originality, important utility, rigor and supporting evidence. [Scope](https://journals.plos.org/digitalhealth/s/journal-information), [article types](https://journals.plos.org/digitalhealth/s/what-we-publish). | **Primary preparation target.** The biomedical data-access problem, Agent-assisted scientific construction, usable tables and analysis-centered evaluation form a coherent applied-methods article. The best-fitting submission section is Database Creation and Curation; that section choice is our interpretation, not a preclearance. |
| **Journal of Biomedical Informatics — Original Research** | The publisher lists original research and emphasizes broadly applicable informatics methodology, conceptual contributions or generalizable project lessons. Its scope expects comparison with current approaches and healthcare-professional involvement in motivation/evaluation. AMIA corroborates these points. [Publisher description](https://shop.elsevier.com/journals/journal-of-biomedical-informatics/1532-0464), [AMIA description](https://amia.org/news-publications/journals/journal-biomedical-informatics). | **Conditional alternative, not an easier fallback.** A stronger fit if the paper makes the general evidence-to-model method and transferable lessons its center. Explain why study-specific operators and joint completion change a class of biomedical synthesis problems. Describe any real domain-expert contribution accurately; Agent reviewers are not healthcare professionals. |
| **npj Digital Medicine — Article** | The scope centers digital medicine and innovative, validated clinical AI/informatics applications, and says small preliminary studies and clinical work using off-the-shelf AI are generally not considered. Articles report substantial original research. [Aims](https://www.nature.com/npjdigitalmed/aims), [content types](https://www.nature.com/npjdigitalmed/content-types). | **Stretch, not recommended first for this package.** The current evidence concerns research-data construction and reconstruction, with no independent clinical-use demonstration. A new algorithm or wet laboratory is not inherently required, but Agent branding or larger synthetic tables does not establish the clinical/scientific significance expected by this scope. |

The npj scope statement does not mean that all research using an existing LLM is ineligible. The concern is the demonstrated contribution and use. Likewise, JBI's comparative expectation is not a requirement to optimize an unlimited bespoke statistical opponent for every case. The completed references should be described fairly; unsupported superiority language should simply be absent.

## PLOS requirements that affect preparation now

**Method utility and validation.** The journal asks a method/tool submission to achieve its intended use and improve on existing options in some respect where applicable. A proof-of-principle experiment or analysis can address this requirement; successful execution alone is not enough. This is an actual policy criterion, not a demand introduced by this project. **Presentation:** no general manuscript word/figure limit is imposed; the abstract is at most 300 words; a separate 150-200-word, first-person, nontechnical Author Summary is requested. English, single-column double spacing, continuous line numbers and Vancouver references are specified. Initial submission is flexible if information needed for review is present. [Submission guidelines](https://journals.plos.org/digitalhealth/s/submission-guidelines).

**Software availability.** Where software is central, PLOS requires open-source software in an appropriate open archive, linked from the manuscript, with installation/use documentation and test data/control settings. The code-sharing policy explicitly calls for a suitable license; a publicly readable repository is not itself that license. [Software/code policy](https://journals.plos.org/digitalhealth/s/materials-software-and-code-sharing).

**Data availability.** A statement must explain how to obtain the data needed to reproduce the findings. Legitimate legal or ethical restrictions may be described with the access route; the minimum dataset includes underlying values and relevant metadata/methods. An aggregate figure package is useful but should not be represented as the complete dataset for every scientific finding. [Data policy](https://journals.plos.org/digitalhealth/s/data-availability).

These are preparation requirements, not permission to upload participant-level records, generated rows, third-party papers or restricted codebooks. The user's existing local-only rules remain. The submission plan must describe lawful access and what the public code can reconstruct.

## Writing choices for this article

These are manuscript-specific recommendations, rather than extra journal rules:

1. **Open with the biomedical data gap.** Researchers have partial published knowledge but lack the joint records needed for their proposed analysis. The data product, scientific use and Agent decisions should be visible before implementation infrastructure.
2. **Make the numerical translation example central.** Show how two separately adjusted source projections cannot simply be pasted into a multivariable equation, and how the Agent supplies a covariate law and residual-dependence assumption. This concrete operation distinguishes scientific construction from a generic code-generation demonstration. Preserve the example's unverified assumptions and observed discrepancy.
3. **Frame the added capability precisely.** Relative to workflows requiring individual training records or fully specified simulation rules, this procedure accepts curated partial study findings and constructs an executable joint model. This is an input/capability distinction, not a field-wide first or an observed human-effort saving. Filshtein, SynthIPD, G-Sim and LLMSynthor already establish related capabilities; retain the existing source-based discussion.
4. **Keep the three experiments separate and purposeful.** The first tests analytical agreement from external evidence; the second tests what supplied summaries permit; the third tests a complete repeated-measure data product and public-law reconstruction. They are not a pooled benchmark, a controlled information ladder or three new clinical confirmations.
5. **Report usefulness through scientific results.** Present requested effect scales, adjusted associations and longitudinal interactions together with important failures. Distributional checks diagnose model limits; they do not replace the downstream analysis question. No new favorable-result search is needed.
6. **Explain how a researcher should interpret the output.** The table permits analysis of the model implied by available evidence and stated completion assumptions. A changing research request may lead to a different generator. Extra synthetic rows improve Monte Carlo precision but do not add clinical knowledge.
7. **Give the reusable method a clear public entry point.** Link the construction contracts, scientific model examples, permitted evidence summaries, frozen specifications and separate aggregate reproduction command. Label what is executable today and which model dispatch or clinical access remains environment-specific.

## Submission preparation checklist

The following status is based on the current project artifacts; it is not a journal-compliance certification.

| Item | Current state | Focused action |
|---|---|---|
| Scientific story and empirical support | Three completed settings, complete outcomes and worked numerical example are available | Revise prose around the concrete capability; retain all endpoint exceptions and distinct information meanings. |
| Numerical displays | Four main figures plus S1 and four main tables are assembled; aggregate rerendering is independently checked | Keep verified data and plotting code; inspect at the final publication size when formatting. |
| Abstract and Author Summary | v0.8 prose is being prepared; the [provisional submission text](SUBMISSION_TEXT_v08_2026-11-03.md) now supplies a 177-word nontechnical, first-person Author Summary and a cover-letter scientific paragraph | The summary matches the verified format guidance and current evidence; author review remains pending. Avoid adding claims during compression or public-language rewriting. |
| Software license and reuse | Filename-only check of the public checkout found no tracked LICENSE/LICENCE/COPYING file; this does not establish ownership rights | Authors should determine the appropriate license for original contributions and separate third-party code terms. Do not insert a license without that decision. |
| Data/code availability | Public protocols, code, aggregates and a display-reproduction route exist; clinical/generation reruns have separate requirements | List exact public artifacts and lawful cohort-access paths; identify what each route reproduces. Do not promise unrestricted original data or clinical rerun. |
| Human/organizational declarations | Authorship, contribution, funding, competing interests, access/ethics and AI-use fields remain author-specific | Complete them from actual records. Neither public-data status nor software audit establishes an ethics determination. |
| Article type and package | Primary target and section are recommended here; no submission has occurred | Prepare a methods Research Article with an appropriate Author Summary, availability statements and a concise cover letter after author review. |

The public license check was limited to tracked filenames at the current local public checkout. It did not inspect restricted materials or make a legal determination. The author can resolve this alongside ordinary submission declarations; it is not a reason to halt prose editing.

## What does not need to be added for this preparation route

Do not launch another dataset search, enlarge the synthetic sample merely for scale, force a positive revision result, or require a multi-Agent ablation. Do not mandate a new training loss or a universal Agent-versus-statistics win. The completed public-law comparison and statistical references can be retained at their actual information conditions.

A favorable independent target would support a stronger transport claim, and an original-document extraction audit would support assisted evidence processing. Neither is required to describe the current bounded result, and neither is initiated by choosing a preparation venue. The earlier feasibility audit did not admit a fresh case. The submission's main unresolved question is whether the *demonstrated incremental capability and scientific use* are sufficiently consequential to readers; the paper should answer that through its existing model trace, cases and comparative positioning.

## Access record and limits

- PLOS scope, article types, submission instructions, software policy and data policy were directly read from official journal pages on the date above.
- The JBI ScienceDirect guide-for-authors endpoint returned HTTP 403. The publisher's Elsevier Shop description and AMIA page were accessible and consistent. No JBI formatting limit is asserted; verify its current guide if choosing that alternative.
- Direct npj aims/content-type opens encountered an identity-provider redirect. The official-page content was available in the web search index and used only for the stated scope and article-type facts. This distinction is retained rather than claiming a successful direct full-page open.
- No impact factors, acceptance probabilities, APC estimates, review-time promises, new prior-work priority claims or fourth venue were added.
- This memo uses the current draft and [follow-up decision](FOLLOWUP_DECISION_v07_2026-11-03.md). The older six-venue memo remains historical; its pending HRS/reproduction descriptions are superseded by the completed evidence.
